Valneva to start final phase trials of its COVID-19 vaccine this month
Category: #health  | By Nikita Chaurasia  | Date: 2021-04-07 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Valneva to start final phase trials of its COVID-19 vaccine this month

In recent developments, French biotechnology organization Valneva SE has announced positive results in the early-stage clinical trials of its inactivated COVID-19 vaccine candidate, VLA2001. Following the recent development, the company’s shares went up by 8% in early Paris trading.

For those unaware, Valneva is a specialty vaccine manufacturer which primarily focuses on the commercialization and development of prophylactic vaccines for infectious diseases with unmet medical needs. The organization is headquartered in France and has manufacturing facilities across Austria, Sweden, and Scotland.

If sources are to be believed, the clinical trial round involved 153 participants administered three dosage levels following a schedule of two doses with a time interval of three weeks. The test found that Valneva’s vaccine, in combination with Dynavax Technologies’ CpG 1018(TM) adjuvant, was highly immunogenic and safe.

Valneva indicated that the trials showcased substantial levels of antibodies to the Coronavirus spike protein in more than 90% of the candidates. Moreover, no safety concerns were raised by the Data Safety Monitoring Board.

According to reliable sources, Valneva has signed a deal with the British government for supplying around 190 doses of its COVID-19 vaccine by 2025 in a transaction potentially worth more than €1.4 billion (USD 1.65 billion).

The company has been working closely with British regulatory authorities for reviewing plans for potential variant vaccine development as well as supply.

In other news, French authorities have converted the country’s largest stadium, The Stade de France, into a COVID-19 vaccination center, in an attempt to accelerate the administration of the vaccine jabs amid the third wave of the pandemic in France.

The stadium has a seating capacity of more than 80,000 and is one of the 40 vaccine centers to be established in the country.

Source credits- https://www.theedgemarkets.com/article/valneva-start-final-tests-alternative-covid19-vaccine

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

Goldman Sachs provides unlimited holidays to its senior employees

Goldman Sachs provides unlimited holidays to its senior employees

By Nikita Chaurasia

Goldman Sachs has recently announced a flexible vacation scheme under which the company’s senior employees can take unlimited paid leaves annually. As per sources, the global investment bank has unveiled a new policy that will allow senior sta...

Shell trades off Russian retail business to native oil producer Lukoil

Shell trades off Russian retail business to native oil producer Lukoil

By Nikita Chaurasia

Energy giant Shell plans on selling more than 400 petrol stations of its Russian subsidiary Shell Neft to Lukoil, the second largest oil producer in the country after state backed Rosneft. As several Western oil and gas firms seek to get rid of th...

Mitsubishi, Siemens sign an MoU to cooperate in SiC traction technology

Mitsubishi, Siemens sign an MoU to cooperate in SiC traction technology

By Nikita Chaurasia

Mitsubishi Electric Europe and Siemens Mobility have recently signed a memorandum of understanding (MoU) to work together in silicon carbide (SiC) traction power technology. As per reports, JR Central’s next-generation N700S Shinkansen train...